Ono Pharmaceutical Management
Management criteria checks 4/4
Ono Pharmaceutical's CEO is Gyo Sagara, appointed in Sep 2008, has a tenure of 16.83 years. total yearly compensation is ¥190.00M, comprised of 41.1% salary and 58.9% bonuses, including company stock and options. directly owns 0.03% of the company’s shares, worth ¥227.33M. The average tenure of the management team and the board of directors is 2.3 years and 5.1 years respectively.
Key information
Gyo Sagara
Chief executive officer
JP¥190.0m
Total compensation
| CEO salary percentage | 41.05% |
| CEO tenure | 16.8yrs |
| CEO ownership | 0.03% |
| Management average tenure | 2.3yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
Ono Pharmaceutical (TSE:4528) Will Pay A Dividend Of ¥40.00
Jul 10
Is Ono Pharmaceutical (TSE:4528) A Risky Investment?
Jun 23Earnings Miss: Ono Pharmaceutical Co., Ltd. Missed EPS By 12% And Analysts Are Revising Their Forecasts
May 11Earnings Miss: Ono Pharmaceutical Co., Ltd. Missed EPS By 40% And Analysts Are Revising Their Forecasts
Feb 05The Market Doesn't Like What It Sees From Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Earnings Yet
Dec 16Is Ono Pharmaceutical (TSE:4528) A Risky Investment?
Nov 25Ono Pharmaceutical Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 03We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt
Aug 25Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | JP¥50b |
| Dec 31 2024 | n/a | n/a | JP¥74b |
| Sep 30 2024 | n/a | n/a | JP¥95b |
| Jun 30 2024 | n/a | n/a | JP¥121b |
| Mar 31 2024 | JP¥190m | JP¥78m | JP¥128b |
| Dec 31 2023 | n/a | n/a | JP¥128b |
| Sep 30 2023 | n/a | n/a | JP¥125b |
| Jun 30 2023 | n/a | n/a | JP¥115b |
| Mar 31 2023 | JP¥228m | JP¥77m | JP¥113b |
Compensation vs Market: Gyo's total compensation ($USD1.29M) is about average for companies of similar size in the JP market ($USD1.11M).
Compensation vs Earnings: Gyo's compensation has been consistent with company performance over the past year.
CEO
Gyo Sagara (67 yo)
Mr. Gyo Sagara has been the Chief Executive Officer at Ono Pharmaceutical Co., Ltd since April 01, 2024 and serves as it’s Director and served as its President since September 2008 until April 01, 2024 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 16.8yrs | JP¥190.00m | 0.030% ¥ 227.3m | |
| President | 1.3yrs | no data | 0.012% ¥ 91.9m | |
| Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning | 2yrs | no data | no data | |
| Corporate Officer & Head of Risk and Compliance Management Department | 2.5yrs | no data | no data | |
| Executive Officer | 2.5yrs | no data | no data | |
| Corporate Officer & Deputy Executive Director | no data | no data | no data | |
| Corporate Officer & Head of Medical Affairs | no data | no data | no data | |
| Senior Director of EHS Promotion & Corporate Executive Officer | no data | no data | no data | |
| Corporate Executive Officer &Exe. Dir. of CMC & Production | less than a year | no data | no data | |
| Head of Development Div. | no data | no data | no data | |
| Corporate Officer & Head of Quality Assurance Division | no data | no data | no data | |
| Corporate Officer | no data | no data | no data |
Experienced Management: 4528's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 19.1yrs | JP¥190.00m | 0.030% ¥ 227.3m | |
| President | 5.1yrs | no data | 0.012% ¥ 91.9m | |
| EVP, Executive Director of Corporate Strategy & Planning | 5.1yrs | no data | 0.0081% ¥ 61.3m | |
| Independent Outside Director | 4.1yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 5.1yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 9.1yrs | no data | no data | |
| Audit & Supervisory Board Member | 1.1yrs | no data | 0.0038% ¥ 29.0m | |
| Independent Outside Director | 7.1yrs | no data | no data | |
| Independent Outside Director | 5.1yrs | no data | no data | |
| Chairman of Audit Supervisory Board | 4.1yrs | no data | 0.00043% ¥ 3.3m |
Experienced Board: 4528's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/14 08:16 |
| End of Day Share Price | 2025/07/14 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ono Pharmaceutical Co., Ltd. is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Aaron Ho | CFRA Equity Research |